But its a long-term play: Payers must analyze and establish longer-term ROI Even if payers actively want to keep up with the wave of demand for GLP-1s to treat obesity, they ultimately must convince plan sponsors to buy in
It is classified into two main types: soluble and insoluble fiber
If successful, it would offer GLP-1 activation without peptide stability concerns, cold chain requirements, or injection needles
In supplement form, however, this essential mineral is typically paired with another compound, which can affect everything from how well it's absorbed to how it works in the body
Personalization A personalized approach is crucial, with many physicians advocating for tailored treatment plans that consider individual needs and comorbidities
Additionally, by pre-treating with the GRP receptor antagonist RC-3095, they found that GRP also plays a partial role in metformin-induced GLP-1 secretion